Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric finerenone study in chronic kidney disease with proteinuria
2023-504884-17-00Phase 3Authorised
- Sponsor
- Bayer
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 32
01
Overview
Phase 3, randomised, double-blind trial in chronic kidney disease (CKD) comparing Finerenone + ACEI or ARB with Placebo + ACEI or ARB (2 arms). Primary endpoint: Mean reduction from baseline to Month 6 in urinary protein-to-creatinine ratio. Planned start Feb 2022; status: authorised.
02
Drugs
finerenone
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2023-504884-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504884-17-00.